Emergent BioSolutions (NYSE:EBS) Issues Quarterly Earnings Results

Emergent BioSolutions (NYSE:EBS) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.40, Zacks reports. The company had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter last year, the business posted ($0.77) earnings per share. Emergent BioSolutions updated its FY 2025 guidance to EPS.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS opened at $6.85 on Tuesday. Emergent BioSolutions has a fifty-two week low of $1.82 and a fifty-two week high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company has a market capitalization of $371.16 million, a price-to-earnings ratio of -1.67 and a beta of 1.62. The firm’s 50 day simple moving average is $9.52 and its 200 day simple moving average is $9.08.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EBS shares. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Finally, StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Monday, February 17th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.